We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 31, 2022

First-in-Human HER2-Targeted Bispecific Antibody KN026 for HER2-Positive Metastatic Breast Cancer

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
Clin. Cancer Res 2022 Jan 04;[EPub Ahead of Print], J Zhang, D Ji, L Cai, H Yao, M Yan, X Wang, W Shen, Y Du, H Pang, X Lai, H Zeng, J Huang, Y Sun, X Peng, J Xu, J Yang, F Yang, T Xu, X Hu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading